Cellebrite DI (CLBT) Shares Jumped, What Is Behind The Move?

AI release puts Cellebrite DI in focus

Cellebrite DI (CLBT) just rolled out its Autumn 2026 Release, with the Genesis AI suite and broader forensic capabilities giving investors fresh context for how the business is positioning its product roadmap.

The Autumn 2026 Release appears to have sharpened sentiment around Cellebrate DI, with the US$12.10 share price supported by a 1 month share price return of 12.14% and a 7 day gain of 8.57%. This comes even though the 1 year total shareholder return is down 34.59%, while the 3 year total shareholder return is up 81.95%.

Scan other AI focused forensic and security players that could see similar momentum with our hand picked 39 profitable AI stocks that aren't just burning cash as Cellebrite DI pushes its Genesis suite to the forefront.

Cellebrite DI now appears to be a stronger operation, with AI at the center of its toolkit. After the recent jump in CLBT, the more difficult question is whether that progress is already reflected in the price.

Most Popular Narrative: 21% Undervalued

Cellebrite DI's most followed narrative pegs fair value at $15.36, compared with the latest $12.10 close, which frames the Autumn 2026 AI launch against expectations for future cash generation and risk.

The continued transition to a recurring, subscription-based revenue model with over 90% of revenues now from subscriptions and growing SaaS and cloud penetration improves revenue visibility, predictability, and operating leverage, which is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.

See why 20 investors see Cellebrite DI as 21% undervalued.

Result: Fair Value of $15.36 (UNDERVALUED)

Still, concentration risk around US federal contracts and the recent CEO change could unsettle confidence in Cellebrite DI if execution wobbles again.

Find out about the key risks to this Cellebrite DI narrative.

Another view on Cellebrite DI's valuation

On cash flows, Cellebrite DI looks modestly cheap. At $12.10, the stock trades about 15.9% below the SWS DCF model estimate of fair value at $14.38. This points to a smaller gap than the $15.36 narrative number, raising the question of which anchor to use as your reference point.

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Sitting between fresh AI optimism and recent share price pressure, Cellebrite DI now needs your verdict. Move quickly, weigh both the concerns and the upside, then test that view against the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Cellebrite DI?

If you stop with Cellebrite DI, you only see one angle. Use the Simply Wall Street screener to pressure test your thesis and surface fresh opportunities fast.

• Target steadier compounding by focusing on resilient businesses in the 30 resilient stocks with low risk scores that may hold up better when sentiment swings.
• Hunt for quality at a discount by checking the 28 high quality undervalued stocks that score well on fundamentals but still trade below their estimated worth.
• Get ahead of the crowd by scanning the 21 high quality undiscovered gems where strong balance sheets and solid metrics have not yet attracted broad attention.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com